Affimed (NASDAQ:AFMD) Receives $13.50 Average Price Target from Analysts

Affimed (NASDAQ:AFMD) has been given an average recommendation of “Moderate Buy” by the five brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $13.50.

AFMD has been the subject of several recent research reports. StockNews.com assumed coverage on Affimed in a research note on Tuesday, April 1st. They issued a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Affimed in a research report on Tuesday, December 10th. Finally, Wells Fargo & Company lowered their price target on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th.

Affimed Price Performance

Shares of Affimed stock opened at $0.57 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a twelve month low of $0.56 and a twelve month high of $8.95. The firm’s 50-day moving average price is $0.94 and its 200 day moving average price is $1.98.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Affimed during the third quarter worth about $44,000. FMR LLC increased its holdings in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the last quarter. Intellectus Partners LLC increased its holdings in shares of Affimed by 34.0% during the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 32,053 shares during the last quarter. Northern Trust Corp purchased a new stake in shares of Affimed during the 4th quarter valued at approximately $218,000. Finally, Point72 Asset Management L.P. lifted its holdings in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the last quarter. Hedge funds and other institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.